New Research Study: A Behavioral Activation App for Depression During Pregnancy
We are now recruiting for a study using a novel app using behavioral activation to treat depression during pregnancy.
New Research from the CWMH: No Increase in Major Malformations in Children Prenatally Exposed to Aripiprazole
Despite the increasing use of the newer atypical or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including psychotic disorders, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little [...]
Recruiting New Mothers with Postpartum Depression for the Skylark Study
In 2019, brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression. The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]
New Research from the CWMH: The Course of ADHD During Pregnancy
We continue to see an increasing number of women with attention-deficit/hyperactivity disorder (ADHD) who are either pregnant or planning to conceive. While we have considerable data to indicate that women with mood and anxiety [...]
New Research Study: Pregnenolone Neurosteroid for the Treatment of Menopausal Depression
Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. This class of compounds are steroid hormones produced in the brain and endocrine tissues which can [...]
New Research from the CWMH: Impact of Obesity on Pregnancy Outcomes in Women with Psychiatric Illness
Individuals with psychiatric disorders are at higher risk for obesity than the general population, as well as for medical comorbidity, such as diabetes, hypertension, hyperlipidemia, and cardiovascular disease. Because obesity is associated with an [...]
New Research from the CWMH: Vortioxetine Effective for Depression and Menopausal Symptoms
As women transition into the menopause, they experience a constellation of symptoms including vasomotor symptoms (hot flashes and night sweats), sleep disruption, problems with sexual functioning, and cognitive impairment. Women may also be more [...]
Recruiting at CWMH: A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
Women are twice as likely as men to have major depressive disorder (MDD) during their lifetimes, and women are particularly at risk during the menopausal transition (including perimenopause and early menopause), which can last [...]
Research from the CWMH: How MsFLASH Informs the Treatment of Menopausal SymptomsÂ
In 2008, the National Institutes of Health funded the Menopause Strategies: Finding Lasting Answers for Symptoms and Health or MSFlash clinical trials network. The primary goal of MSFlash has been to find and test [...]
New Research from the CWMH: Prenatal Supplement Containing Folate May Reduce Depressive Symptoms During Pregnancy
While there is research to support the reproductive safety of many antidepressants, many woman and their providers ask about alternatives to traditional antidepressants in women who are pregnant or planning to conceive. Â In a [...]